ArticleUrologic oncology2021

Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.

Ali Raza Khaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.